At the center of every clinical trial is a group of patients, each with a medical condition that we seek to understand more about through interacting with those patients directly. Startups like Sanguine Biosciences are part of a clinical services innovation layer, connecting population health, clinical research, and healthcare delivery in new ways using new technologies.
On this episode, our guest is Brian Neman, CEO of Sanguine Biosciences, and adjunct instructor at the University of Southern California’s Price School of Public Policy. We discuss how recent technological advancements enable new ways of making clinical research that improves safety, efficacy, and efficiency, and—-critically in the time of COVID-19–improved continuity of care and medical research.
This is the TomorrowScale Podcast. Hosted by Justin Briggs.
Sanguine Biosciences: https://sanguinebio.com
Listen on Your Favorite Podcast App
Disclosures: The host and guest have no conflicts to disclose. Mr. Briggs and companies he is affiliated with are not current or previous clients of Sanguine Biosciences.
The TomorrowScale Podcast was created to showcase scientists and entrepreneurs who are building science-based businesses, and to hear their stories from the benches and in the trenches of research & development. The views expressed by the host and guests are their own, and the content of this show should not be considered legal, tax, or investing advice. Thanks to our guests for sharing their time and knowledge with us. Thank you for listening. Please science responsibly.